Bioxytran (BIXT) Stock Chart & Stock Price History $0.08 -0.01 (-8.11%) As of 08/25/2025 03:07 PM Eastern Add Compare Share Share Chart Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock Bioxytran Stock Price Performance The Bioxytran (BIXT) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 23.76%, with a year-to-date return of -14.35%. In the past month, the stock has decreased 10.47%, reflecting recent market activity. As of the latest close, Bioxytran traded at $0.08 with a market cap of $6.85 million and volume of 150,290 shares. Receive BIXT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-3.75%1 Month Performance-10.47%3 Month Performance-49.21%Year-To-Date Performance-14.35%1 Year Performance-23.76% BIXT Stock Chart for Tuesday, August, 26, 2025 BIXT Chart by TradingView Bioxytran Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/25/2025$0.08$0.08-8.11%$0.08$0.08150,290 shs$6.85 million08/22/2025$0.08$0.08+4.75%$0.08$0.08312,829 shs$7.46 million08/21/2025$0.08$0.08+5.26%$0.08$0.0812,125 shs$7.12 million08/20/2025$0.08$0.08-2.19%$0.08$0.0844,213 shs$6.76 million08/19/2025$0.08$0.08-3.60%$0.08$0.0853,600 shs$6.92 million08/18/2025$0.08$0.08+0.75%$0.08$0.08161,922 shs$7.17 million08/15/2025$0.08$0.08-4.99%$0.08$0.07169,735 shs$7.12 million08/14/2025$0.08$0.08+7.40%$0.08$0.07291,275 shs$7.49 million08/13/2025$0.08$0.08+1.03%$0.08$0.08239,217 shs$6.98 million08/12/2025$0.08$0.08-8.38%$0.09$0.08117,787 shs$6.91 million Get the Latest News and Ratings for BIXT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. 08/11/2025$0.08$0.08+5.87%$0.09$0.0867,521 shs$7.54 million08/08/2025$0.08$0.08+0.13%$0.09$0.0894,913 shs$7.12 million08/07/2025$0.08$0.08-2.44%$0.08$0.0827,800 shs$7.11 million08/06/2025$0.08$0.08-0.12%$0.08$0.0847,514 shs$7.29 million08/05/2025$0.09$0.08-3.53%$0.09$0.088,900 shs$7.30 million08/04/2025$0.09$0.09-5.56%$0.09$0.08110,713 shs$7.56 million08/01/2025$0.09$0.09-4.26%$0.10$0.0937,250 shs$8.01 million07/31/2025$0.09$0.09+3.98%$0.10$0.0882,613 shs$8.37 million07/30/2025$0.09$0.09+3.91%$0.09$0.0832,003 shs$8.05 million07/29/2025$0.08$0.09+5.58%$0.09$0.08106,615 shs$7.74 million07/28/2025$0.09$0.08-4.19%$0.09$0.08145,402 shs$7.33 million07/25/2025$0.09$0.09-6.42%$0.09$0.0837,301 shs$7.65 million Related Companies Generation Bio Stock Chart Rein Therapeutics Stock Chart OnKure Therapeutics Stock Chart Dyadic International Stock Chart Biodexa Pharmaceuticals Stock Chart JATT Acquisition Stock Chart Tenax Therapeutics Stock Chart NanoViricides Stock Chart FibroBiologics Stock Chart Natural Alternatives International Stock Chart Receive BIXT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:BIXT) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxytran With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access